Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
Conditions: Cognitive Decline; Intracerebral Hemorrhage; Dementia, Vascular; Cerebral Small Vessel Diseases; Hypertension; Stroke Hemorrhagic Interventions: Drug: telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg; Drug: Placebo oral capsule Sponsors: The George Institute; University of Sydney Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials